Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer

X. S. Chen, X. Q. Nie, C. M. Chen, J. Y. Wu, J. Wu, J. S. Lu, Z. M. Shao, Z. Z. Shen, K. W. Shen

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Background: To evaluate the activity and safety of nonanthracycline-containing weekly PCb [paclitaxel (Taxol) plus carboplatin] regimen in neoadjuvant treatment of breast cancer. Patients and methods: Eligible patients were assigned to receive four cycles of PCb with dose of paclitaxel 80 mg/ m2 and carboplatin at an area under the curve of 2 mg × min/ml, given day 1, day 8 and day 15 of every 4 weeks. Pathological complete remission (pCR) was defined as no invasive cancer in breast and axillary samples. Results: Overall, 107 consecutive patients received weekly PCb treatment from December 2007 to December 2008, and one was diagnosed with bilateral breast cancer. A total of 85.2% of patients were initially diagnosed with stage III diseases. Clinical response rate was 86.1% with complete remission rate 32.4%. Twenty-one patients achieved pCR after neoadjuvant treatment, with pCR rate 19.4%. The incidence of grade 3-4 neutropenia was 40.2% and only one patient was reported with febrile neutropenia. Severe anemia and thrombocytopenia occurred in 4.7% and 0.9%, respectively, of patients. Peripheral neuropathy was frequent but never severe. Patients with estrogen receptor-negative, progesterone receptor-negative, triple-negative or human epidermal growth factor receptor 2 (Her2)-positive subtype disease had higher pCR. Conclusions: Weekly PCb regimen was very active and tolerable as neoadjuvant treatment of breast cancer. This weekly PCb regimen should consider as a reasonable nonanthracycline-containing option in the neoadjuvant treatment of breast cancer.

Original languageEnglish (US)
Pages (from-to)961-967
Number of pages7
JournalAnnals of Oncology
Volume21
Issue number5
DOIs
StatePublished - Mar 8 2010

Fingerprint

Carboplatin
Paclitaxel
Breast Neoplasms
Drug Therapy
Neoadjuvant Therapy
Febrile Neutropenia
Peripheral Nervous System Diseases
Progesterone Receptors
Neutropenia
Thrombocytopenia
Estrogen Receptors
Area Under Curve
Anemia
Safety

Keywords

  • Breast cancer
  • Carboplatin
  • Neoadjuvant chemotherapy
  • Paclitaxel
  • Weekly administration

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. / Chen, X. S.; Nie, X. Q.; Chen, C. M.; Wu, J. Y.; Wu, J.; Lu, J. S.; Shao, Z. M.; Shen, Z. Z.; Shen, K. W.

In: Annals of Oncology, Vol. 21, No. 5, 08.03.2010, p. 961-967.

Research output: Contribution to journalArticle

Chen, X. S. ; Nie, X. Q. ; Chen, C. M. ; Wu, J. Y. ; Wu, J. ; Lu, J. S. ; Shao, Z. M. ; Shen, Z. Z. ; Shen, K. W. / Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. In: Annals of Oncology. 2010 ; Vol. 21, No. 5. pp. 961-967.
@article{ed451561075c402891ed399b36a65a70,
title = "Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer",
abstract = "Background: To evaluate the activity and safety of nonanthracycline-containing weekly PCb [paclitaxel (Taxol) plus carboplatin] regimen in neoadjuvant treatment of breast cancer. Patients and methods: Eligible patients were assigned to receive four cycles of PCb with dose of paclitaxel 80 mg/ m2 and carboplatin at an area under the curve of 2 mg × min/ml, given day 1, day 8 and day 15 of every 4 weeks. Pathological complete remission (pCR) was defined as no invasive cancer in breast and axillary samples. Results: Overall, 107 consecutive patients received weekly PCb treatment from December 2007 to December 2008, and one was diagnosed with bilateral breast cancer. A total of 85.2{\%} of patients were initially diagnosed with stage III diseases. Clinical response rate was 86.1{\%} with complete remission rate 32.4{\%}. Twenty-one patients achieved pCR after neoadjuvant treatment, with pCR rate 19.4{\%}. The incidence of grade 3-4 neutropenia was 40.2{\%} and only one patient was reported with febrile neutropenia. Severe anemia and thrombocytopenia occurred in 4.7{\%} and 0.9{\%}, respectively, of patients. Peripheral neuropathy was frequent but never severe. Patients with estrogen receptor-negative, progesterone receptor-negative, triple-negative or human epidermal growth factor receptor 2 (Her2)-positive subtype disease had higher pCR. Conclusions: Weekly PCb regimen was very active and tolerable as neoadjuvant treatment of breast cancer. This weekly PCb regimen should consider as a reasonable nonanthracycline-containing option in the neoadjuvant treatment of breast cancer.",
keywords = "Breast cancer, Carboplatin, Neoadjuvant chemotherapy, Paclitaxel, Weekly administration",
author = "Chen, {X. S.} and Nie, {X. Q.} and Chen, {C. M.} and Wu, {J. Y.} and J. Wu and Lu, {J. S.} and Shao, {Z. M.} and Shen, {Z. Z.} and Shen, {K. W.}",
year = "2010",
month = "3",
day = "8",
doi = "10.1093/annonc/mdq041",
language = "English (US)",
volume = "21",
pages = "961--967",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer

AU - Chen, X. S.

AU - Nie, X. Q.

AU - Chen, C. M.

AU - Wu, J. Y.

AU - Wu, J.

AU - Lu, J. S.

AU - Shao, Z. M.

AU - Shen, Z. Z.

AU - Shen, K. W.

PY - 2010/3/8

Y1 - 2010/3/8

N2 - Background: To evaluate the activity and safety of nonanthracycline-containing weekly PCb [paclitaxel (Taxol) plus carboplatin] regimen in neoadjuvant treatment of breast cancer. Patients and methods: Eligible patients were assigned to receive four cycles of PCb with dose of paclitaxel 80 mg/ m2 and carboplatin at an area under the curve of 2 mg × min/ml, given day 1, day 8 and day 15 of every 4 weeks. Pathological complete remission (pCR) was defined as no invasive cancer in breast and axillary samples. Results: Overall, 107 consecutive patients received weekly PCb treatment from December 2007 to December 2008, and one was diagnosed with bilateral breast cancer. A total of 85.2% of patients were initially diagnosed with stage III diseases. Clinical response rate was 86.1% with complete remission rate 32.4%. Twenty-one patients achieved pCR after neoadjuvant treatment, with pCR rate 19.4%. The incidence of grade 3-4 neutropenia was 40.2% and only one patient was reported with febrile neutropenia. Severe anemia and thrombocytopenia occurred in 4.7% and 0.9%, respectively, of patients. Peripheral neuropathy was frequent but never severe. Patients with estrogen receptor-negative, progesterone receptor-negative, triple-negative or human epidermal growth factor receptor 2 (Her2)-positive subtype disease had higher pCR. Conclusions: Weekly PCb regimen was very active and tolerable as neoadjuvant treatment of breast cancer. This weekly PCb regimen should consider as a reasonable nonanthracycline-containing option in the neoadjuvant treatment of breast cancer.

AB - Background: To evaluate the activity and safety of nonanthracycline-containing weekly PCb [paclitaxel (Taxol) plus carboplatin] regimen in neoadjuvant treatment of breast cancer. Patients and methods: Eligible patients were assigned to receive four cycles of PCb with dose of paclitaxel 80 mg/ m2 and carboplatin at an area under the curve of 2 mg × min/ml, given day 1, day 8 and day 15 of every 4 weeks. Pathological complete remission (pCR) was defined as no invasive cancer in breast and axillary samples. Results: Overall, 107 consecutive patients received weekly PCb treatment from December 2007 to December 2008, and one was diagnosed with bilateral breast cancer. A total of 85.2% of patients were initially diagnosed with stage III diseases. Clinical response rate was 86.1% with complete remission rate 32.4%. Twenty-one patients achieved pCR after neoadjuvant treatment, with pCR rate 19.4%. The incidence of grade 3-4 neutropenia was 40.2% and only one patient was reported with febrile neutropenia. Severe anemia and thrombocytopenia occurred in 4.7% and 0.9%, respectively, of patients. Peripheral neuropathy was frequent but never severe. Patients with estrogen receptor-negative, progesterone receptor-negative, triple-negative or human epidermal growth factor receptor 2 (Her2)-positive subtype disease had higher pCR. Conclusions: Weekly PCb regimen was very active and tolerable as neoadjuvant treatment of breast cancer. This weekly PCb regimen should consider as a reasonable nonanthracycline-containing option in the neoadjuvant treatment of breast cancer.

KW - Breast cancer

KW - Carboplatin

KW - Neoadjuvant chemotherapy

KW - Paclitaxel

KW - Weekly administration

UR - http://www.scopus.com/inward/record.url?scp=77953327187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953327187&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq041

DO - 10.1093/annonc/mdq041

M3 - Article

C2 - 20211870

AN - SCOPUS:77953327187

VL - 21

SP - 961

EP - 967

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 5

ER -